
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Selling, General & Administrative
OSE Immunotherapeutics SA
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Selling, General & Administrative
-€8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Selling, General & Administrative
-€94.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-21%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Selling, General & Administrative
-€21.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-20%
|
|
G
|
Genfit SA
PAR:GNFT
|
Selling, General & Administrative
-€8.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Selling, General & Administrative
-€12m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Selling, General & Administrative
-€39.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-12%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Selling, General & Administrative?
Selling, General & Administrative
-8m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Selling, General & Administrative amounts to -8m EUR.
What is OSE Immunotherapeutics SA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-10%
Over the last year, the Selling, General & Administrative growth was 12%. The average annual Selling, General & Administrative growth rates for OSE Immunotherapeutics SA have been 3% over the past three years , -10% over the past five years .